Phase 1 Obesity Trial, Recruiting NCT05202353 Sponsor: Boehringer Ingelheim Condition: Obesity
Back to Obesity

Phase 1 Obesity Trial, Recruiting

NCT05202353
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been assessed as generally healthy by a doctor, based on a full health check including physical exam, blood pressure, heart rate, heart tracing (ECG), and blood tests
  • You are between 18 and 65 years old (inclusive)
  • Your Body Mass Index (BMI) is between 30 and 40, and your weight is between 70 kg (about 154 lbs) and 150 kg (about 330 lbs)
  • You are willing and able to sign a consent form before joining the study
  • If you are a woman who could become pregnant, you must be willing to use two forms of contraception, at least one of which is a highly effective method with a failure rate of less than 1% per year when used correctly

Who may not be able to join:

  • You have any abnormal result from your health check (blood pressure, heart rate, or ECG) that a doctor considers medically significant
  • Your resting heart rate is above 100 beats per minute, your top blood pressure number is 160 or higher, or your bottom blood pressure number is 95 or higher
  • Your blood test results show certain high levels, specifically: LDL cholesterol above 160 mg/dL, total cholesterol above 240 mg/dL, triglycerides above 200 mg/dL, or fasting blood sugar above 126 mg/dL and/or a blood sugar average (HbA1c) above 6.5%
  • You have type 1 or type 2 diabetes, or any other ongoing medical condition that a doctor considers significant
  • You have significant problems affecting your stomach, gut, liver, kidneys, lungs, heart, immune system, or hormones
  • You have any condition affecting your brain or nervous system, including seizures of any kind, or a relevant psychiatric disorder
  • You have a history of significant dizziness when standing up, fainting, or blacking out
  • You or a close family member have a history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a related condition called multiple endocrine neoplasia type 2, or you currently have an underactive or overactive thyroid
  • Additional criteria may apply that are not listed here (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-800-243-0127

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
2 December 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Percentage of glucagon (GCG) receptors occupancy in the liver using Positron emission tomography (PET) imaging at End of Treatment (EOT) visit

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov